Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Iovance Biotherapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03526185CT.gov A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | — | Terminated | — | — | — |
NCT01029873CT.gov QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00498979CT.gov Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | — | Completed | — | — | — |
NCT00226473CT.gov Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Iovance Biotherapeutics, Inc. | Approved | BB · 65 |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Irinotecan | Melanoma and Skin Cancer Trials Limited | P2 | BB |
| Relatlimab | Bristol-Myers Squibb | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 75 |
| Lung Cancer | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →